Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty taste test reveals gut hormone secrets in diabetes and obesity

NCT ID NCT02028975

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how tasting fatty acids (like linoleic acid) changes levels of gut hormones in healthy people, those with type 2 diabetes, and obese individuals without diabetes. Researchers measured hormone levels in blood after oral stimulation and compared taste sensitivity between groups. The goal was to find biological markers linked to fat taste perception.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain why some people crave fatty foods and how taste perception changes in obesity and diabetes.
What could go wrong
This is a small, early observational study, not a treatment trial. Results may not lead to any direct medical application.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

81 people

The number who actually took part.

Started

May 2010

Finished

Mar 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * persons who have provided written consent * Healthy volunteers: * Men \> 18 years * 19 \<BMI \< 25 kg.m-2 * Fasting triglyceridemia \< 1.50 g/l * Fasting glycemia \< 1.10 g/l * Without regular medical treatment * Patients with type-2 diabetes: * Men \>18 years * type 2 diabetes (fasting glycemia \> 7 mmol/l at the diagnosis) treated with diet or diet + oral antidiabetics (metformin, and/or insulinsecretion agents \[hypoglycemic sulphonamides, or glinides\] and/or glitazones and/or acarbose) * Stable oral antidiabetic treatment for 3 months * Obese non-diabetic patients: * Men \> 18 years * BMI 30 kg.m-2 * Fasting glycemia \< 1.10 g/l * HbA1c \< 6.0% * Absence of treatment with hypoglycemic agents (including benfluorex) * Absence of medical treatment for obesity * Absence of a history of surgery for obesity (band, by-pass) or gastric stimulator (type Tantalus) Exclusion Criteria: * Persons not covered by the national health insurance * Smokers, or smoking cessation within the 3 months preceding inclusion * Persons with eating disorders: * Severe digestive disease (enteropathy with absorption disorders, inflammatory digestive disease) * Pancreatic insufficiency * History of pancreas surgery * Type 1 diabetes * Renal insufficiency * Hepatic insufficiency * Treatment with proton pump inhibitors, insulin, GLP-1 analogues, DPP-4 inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes or obesity without diabetes

Contacts and locations

Locations

  • CHU Dijon

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.